

Merus Labs International Inc.  
Form 6-K  
January 31, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **JANUARY, 2012**

Commission File No. **00-30082**

**MERUS LABS INTERNATIONAL INC.**

(Translation of registrant's name into English)

**Suite 2007, 1177 West Hastings Street  
Vancouver, BC V6E 2K3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F  
**Form 20-F**  **Form 40-F**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1)

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7)

Indicate by check mark whether the registrant, by furnishing the information contained in this Form, is also thereby  
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**SUBMITTED HEREWITH**

| <b>Exhibits</b> |  |
|-----------------|--|
| <u>99.1</u>     | <u>Consolidated Financial Statements for the Period Ended November 30, 2011</u>                        |
| <u>99.2</u>     | <u>Management's Discussion and Analysis for the Period Ended November 30, 2011</u>                     |
| <u>99.3</u>     | <u>Form 52-109FV2 - <i>Certification of Interim Filings Venture Issuer Basic Certificate</i> - CEO</u> |
| <u>99.4</u>     | <u>Form 52-109FV2 - <i>Certification of Interim Filings Venture Issuer Basic Certificate</i> - CFO</u> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 31, 2012

**MERUS LABS INTERNATIONAL INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer